U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827742) titled 'Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease' on July 09.
Brief Summary: The purpose of this study is to determine whether Rituximab is safe and effective as a maintenance strategy in individuals with stabilized systemic sclerosis in adults.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis in Adults
Intervention:
DRUG: Rituximab
500mg i.v at M0, M6 and M12
DRUG: Placebo
500mg i.v at M0, M6 and M12
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Assistance Publique - Hopitaux de Paris
Published by HT Digital Content Services with permission fr...